- ►annals.org RB Cohen, JM Abdallah, JR Gray, F … - Annals of internal medicine, 1993 - Am Coll Physicians Fludarabine phosphate is approved for the treatment of advanced B-cell chronic lymphocytic leukemia
refractory to alkylating agents. We report two cases of disabling but reversible neurotoxicity in a
patient with mycosis fungoides and ... Cited by 30 - Related articles - BL Direct - All 4 versions
DE Merkel, NL Griffin, K Kagan-Hallet, DD Von … - Cancer treatment …, 1986 - ncbi.nlm.nih.gov A serious delayed neurotoxicity marked by encephalopathy and cortical blindness has occurred in
patients treated with fludarabine. This toxicity had only been reported in patients receiving high
doses (ie, aplasia-inducing). We ... Cited by 17 - Related articles - All 3 versions
PW Johnson, J Fearnley, P Domizio, J … - British journal of …, 1994 - pubmedcentral.nih.gov Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This
report describes five cases of unusual neurological illnesses occurring after treatment with
fludarabine. These suggest that ... Cited by 6 - Related articles - BL Direct - All 3 versions
HG Chun, BR Leyland-Jones, SM Caryk, DF … - Cancer treatment …, 1986 - ncbi.nlm.nih.gov Fourteen patients developed severe central nervous system (CNS) toxicity after receiving an
investigational antitumor agent, fludarabine phosphate (FAMP). The CNS toxicity has the distinctive
features of delayed onset and ... Cited by 64 - Related articles - All 4 versions
- ►aacrjournals.org [PDF] DR Spriggs, E Stopa, RJ Mayer, W Schoene, DW Kufe - Cancer Research, 1986 - AACR Fludarabine phosphate (NSC 312878), an adenosine deaminase resist ant analogue of 9-/9-D-
arabinofuranosyladenine, has entered clinical trials. Eleven patients with acute leukemia in relapse
received 14 courses of fludarabine ... Cited by 54 - Related articles - All 3 versions
- ►jcojournal.org [PDF] RP Warrell Jr, E Berman - Journal of Clinical Oncology, 1986 - jcojournal.org Fludarabine phosphate (9-BD-arabinofuranosyl-2- fluoroadenine), a novel purine nucleoside, has dem-
onstrated excellent preclinical antitumor activity and little toxicity in phase I clinical trials.
We evaluated the clinical use of ... Cited by 105 - Related articles - All 5 versions
DD Von Hoff - Seminars in oncology, 1990 - ncbi.nlm.nih.gov There have been six different phase I trials of Fludara IV (fludarabine phosphate) in patients with
solid tumors and three different phase I trials of Fludara IV in patients with acute leukemia. In
addition, one trial of the agent ... Cited by 19 - Related articles
J Cid, M Revilla, A Cervera, F Cervantes, E Munoz, I … - Annals of Hematology, 2000 - Springer Abstract Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disorder of
the central nervous system usually affecting immunocom- promised individuals and is due to infection
of the oli- godendrocytes by the JC ... Cited by 29 - Related articles - BL Direct - All 3 versions
A Zabernigg, H Maier, J Thaler, C Gattringer - Lancet - ncbi.nlm.nih.gov 1: Lancet. 1994 Dec 24-31;344(8939-8940):1780. Late-onset fatal neurological toxicity of
fludarabine. Zabernigg A, Maier H, Thaler J, Gattringer C. Publication Types: Case Reports;
Letter. Mesh Terms: Antineoplastic Agents/adverse effects*; Fatal ... Cited by 12 - Related articles - BL Direct - All 3 versions
- ►ascopubs.org [PDF] CA Puccio, A Mittelman, SM Lichtman, RT … - Journal of Clinical …, 1991 - jco.ascopubs.org FLUDARABINE PHOSPHATE (2-fluoro-ara- AMP) is the first of a series of haloadenine nucleotides to
enter clinical trials. 1 ' 2 This purine antimetabolite is the fluorinated derivative of
9-PD-arabinofuranosyladenine ... Cited by 63 - Related articles - All 6 versions
